Nintedanib is an oral triple angiokinase inhibitor targeting VEGFR, FGFR, and PDGFR pathways to block angiogenesis and suppress tumor growth in cancer and fibrosis research. Reagent-grade; for laboratory research purposes only.
Usually ships within 24 hours.